Gene:
TLE1
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  enhancer of split groucho 1
Alternate Symbols:  ESG; ESG1; GRG1
PharmGKB Accession Id: PA36539

Details

Cytogenetic Location: chr9 : q21.32 - q21.32
GP mRNA Boundary: chr9 : 84198598 - 84303596
GP Gene Boundary: chr9 : 84195598 - 84313596
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Canonical Wnt signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  2. Presenilin action in Notch and Wnt signaling - (Pathway Interaction Database NCI-Nature Curated)
  3. wnt signaling pathway - (BioCarta via Pathway Interaction Database)

Publications related to TLE1: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Significant linkage evidence for a predisposition gene for pelvic floor disorders on chromosome 9q21. American journal of human genetics. 2009. Allen-Brady Kristina, et al. PubMed

LinkOuts

Entrez Gene:
7088
OMIM:
600189
UCSC Genome Browser:
NM_005077
RefSeq RNA:
NM_005077
RefSeq Protein:
NP_005068
MutDB:
TLE1
ALFRED:
LO008019S
HuGE:
TLE1
Comparative Toxicogenomics Database:
7088
ModBase:
Q04724
HGNC:
11837

Common Searches